Financial Performance - Revenue for Q1 2025 was $2.2 million, a significant increase from $0.6 million in Q1 2024, primarily due to research activities under a collaboration agreement with Amgen[7]. - R&D expenses for Q1 2025 were $29.8 million, up from $24.9 million in Q1 2024, driven by increased laboratory supplies and personnel expenses[8]. - G&A expenses for Q1 2025 were $8.6 million, compared to $7.1 million in Q1 2024, mainly due to higher personnel costs[9]. - Net loss for Q1 2025 was $34.1 million, compared to a net loss of $30.1 million in Q1 2024, including net interest income of $2.1 million[10]. - Cash, cash equivalents, and marketable securities as of March 31, 2025, were $251.7 million, expected to fund operations into Q1 2027[12]. - As of March 31, 2025, the company had 129,678,572 shares outstanding, including pre-funded warrants[13]. Research and Development - The company plans to file an IND application for TSC-102-A0301 in the second half of 2025[11]. - TScan is on track to initiate a registrational trial for TSC-101 in the latter half of 2025[11]. - The first patient for multiplex TCR-T therapy is expected to be dosed in the first half of 2025[11]. - The company continues to develop the ImmunoBank for diverse TCR-T therapy candidates targeting various cancer-associated antigens[6].

Core Insights - TScan Therapeutics is advancing its T cell receptor (TCR)-engineered T cell therapies for cancer treatment, with significant milestones expected by the end of 2025 [1][2][4] Corporate Updates - The company appointed Stephen Camiolo as Senior Vice President, Market Access, bringing over 25 years of experience in the pharmaceutical and biotechnology industries [6] - TScan is on track to file an IND application for TSC-102-A0301 targeting HLA-A*03:01 in the second half of 2025 [1][7] - The company continues to develop its ImmunoBank, a collection of TCR-T therapy candidates targeting various cancer-associated antigens [5][13] Clinical Trials - TScan is enrolling patients in the PLEXI-T solid tumor trial and anticipates dosing the first patient with multiplex therapy soon, with safety and efficacy data expected later this year [2][15] - The ALLOHA Phase 1 trial is ongoing, focusing on TSC-101 for treating acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome (MDS) [4][7] Financial Performance - Revenue for Q1 2025 was $2.2 million, a significant increase from $0.6 million in Q1 2024, primarily due to research activities under a collaboration agreement with Amgen [8] - R&D expenses rose to $29.8 million in Q1 2025 from $24.9 million in Q1 2024, driven by increased laboratory supplies and personnel costs [9] - G&A expenses increased to $8.6 million in Q1 2025 from $7.1 million in Q1 2024, mainly due to higher personnel expenses [10] - The net loss for Q1 2025 was $34.1 million, compared to $30.1 million in Q1 2024, with cash and cash equivalents totaling $251.7 million as of March 31, 2025, sufficient to fund operations into Q1 2027 [11][12]

Core Insights - TScan Therapeutics, Inc. announced the acceptance of an abstract for a poster presentation at the ASGCT 28th Annual Meeting, highlighting its focus on TCR-engineered T cell therapies for cancer treatment [1][2]. Company Overview - TScan is a clinical-stage biotechnology company specializing in T cell receptor (TCR)-engineered T cell (TCR-T) therapies aimed at treating cancer patients [3]. - The company's lead TCR-T therapy candidates are designed to prevent relapse in patients with hematologic malignancies following allogeneic hematopoietic cell transplantation, specifically through the ALLOHA™ Phase 1 heme trial [3]. - TScan is expanding its ImmunoBank, a repository of therapeutic TCRs that recognize diverse targets across multiple HLA types, to offer customized multiplex TCR-T therapies for various cancers, as seen in the PLEXI-T™ Phase 1 solid tumor trial [3]. - The company is currently enrolling patients in both clinical programs [3]. Presentation Details - The poster presentation titled "CD45 as a Universal Target for Adjuvant TCR-T Cell Therapy Following Allogeneic Hematopoietic Cell Transplantation" will take place on May 13 from 6:00 - 7:30 p.m. Central Time [2]. - The presentation will be held in the Poster Hall, Hall I2, and materials will be available on the company's website post-presentation [2].